Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
W. Marston Linehan(Massachusetts General Hospital), Alice T. Shaw(Massachusetts General Hospital)
Cited by 65
Related Papers
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
|The Lancet Oncology|2017|647
Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F
|New England Journal of Medicine|2015|484
Recent Advances in Targeting ROS1 in Lung Cancer
|Journal of Thoracic Oncology|2017|259